Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Expression of CYP2D6 in developing human liver.

J M Treluyer1, E Jacqz-Aigrain, F Alvarez

  • 1Institut National de la Santé et de la Recherche Médicale U75, Paris, France.

European Journal of Biochemistry
|December 5, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children.

Antimicrobial agents and chemotherapy·2023
Same author

Simplified Dosing Regimens for Gentamicin in Neonatal Sepsis.

Frontiers in pharmacology·2021
Same author

Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis.

The Journal of antimicrobial chemotherapy·2020
Same author

Population pharmacokinetics of ganciclovir after valganciclovir in renal transplant children.

Antimicrobial agents and chemotherapy·2019
Same author

Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients.

The Journal of antimicrobial chemotherapy·2018
Same author

Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.

British journal of clinical pharmacology·2018

The cytochrome P450 2D6 (CYP2D6) protein concentration rises rapidly after birth, impacting drug metabolism. This early increase in CYP2D6 protein is linked to developmental changes in drug biotransformation.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Developmental Biology

Background:

  • Cytochrome P450 2D6 (CYP2D6) is a key polymorphic enzyme in drug biotransformation.
  • Dextromethorphan serves as a probe drug for assessing CYP2D6 activity.
  • Understanding CYP2D6 ontogenesis is crucial for pediatric pharmacotherapy.

Purpose of the Study:

  • To investigate the developmental expression of CYP2D6 protein and RNA.
  • To correlate CYP2D6 levels with drug-metabolizing activity during development.
  • To explore the regulatory mechanisms of CYP2D6 during human ontogenesis.

Main Methods:

  • Immunochemical determination of CYP2D6 protein concentration.
  • Measurement of CYP2D6 RNA levels.
  • Assessment of dextromethorphan O-demethylation and N-demethylation activity in liver microsomes.

Related Experiment Videos

Main Results:

  • CYP2D6 protein concentration significantly increases within the first week post-birth, irrespective of gestational age.
  • Hepatic CYP2D6 protein is undetectable or very low in most fetuses.
  • The rise in CYP2D6 protein correlates with the onset of dextromethorphan O-demethylation.
  • CYP2D6 RNA is detectable earlier than protein, peaking in newborns and declining in adults.
  • Transcriptional regulation appears dominant, with potential post-transcriptional involvement.

Conclusions:

  • CYP2D6 expression and activity undergo significant developmental changes.
  • Hepatic CYP2D6 protein levels rise rapidly after birth, influencing drug metabolism.
  • Regulation of CYP2D6 during ontogenesis involves both transcriptional and potentially post-transcriptional mechanisms.